Xencor Reports Third Quarter 2023 Financial Results

07.11.2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended ...

Related Keywords

Canada ,John Kuch ,Monjuvi Us Minjuvi ,Xencor Xmab ,Barbaraj Klencke ,Amgen ,Alexion Pharmaceuticals Inc ,Exchange Commission ,Janssen Biotech Inc ,Gilead Sciences ,Life Sciences ,Nasdaq ,Genentech ,Amgen Inc ,Gilead Sciences Inc ,European Society For Medical Oncology ,Xencor Inc ,Omeros Corporation ,Through Royalty Transaction ,Alexion Pharmaceuticals ,European Society ,Medical Oncology ,Sierra Oncology ,Third Quarter ,Nine Months Ended September ,Private Securities Litigation Reform Act ,Comprehensive Income ,Xencor Stock ,Xencor Chart ,Encor Kurs ,Encor Aktie ,